Fredun Pharmaceuticals Ltd.

BSE: 539730 SECTOR: Pharmaceuticals & Drugs  3367   13   2

503.00
+1.35 (0.27%)
BSE: 06 Dec 05:10 PM

Price Summary

Today's High

₹ 505

Today's Low

₹ 485

52 Week High

₹ 637

52 Week Low

₹ 0

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

222.96 Cr.

Enterprise Value

261.47 Cr.

No. of Shares

0.44 Cr.

P/E

52.7

P/B

3.43

Face Value

₹ 10

Div. Yield

0.14 %

Book Value (TTM)

₹  146.64

CASH

1.13 Cr.

DEBT

39.64 Cr.

Promoter Holding

52.04 %

EPS (TTM)

₹  9.55

Sales Growth

18.73%

ROE

4.77 %

ROCE

9.53%

Profit Growth

5.93 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Fredun Pharmaceuticals Ltd.

MAMALAIT GRANULES FREDCAL BIRD AND BEAUTY PURI5 FREPREIMECAL FREOSSITONE GRANULES FREOSSIPOWER

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year18.73%
3 Year31.01%
5 Year25.9%

Profit Growth

1 Year5.93%
3 Year4.79%
5 Year13.5%

ROE%

1 Year4.77%
3 Year8.03%
5 Year14.2%

ROCE %

1 Year9.53%
3 Year13.48%
5 Year14.9%

Debt/Equity

0.9204

Price to Cash Flow

1312.04

Interest Cover Ratio

1.73388189211083

CFO/PAT (5 Yr. Avg.)

1.00665547974546

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2021 52.04 5.54
Jun 2021 52.04 5.54
Mar 2021 52.04 5.54
Dec 2020 52.04 5.54
Sep 2020 52.04 5.54
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good revenue growth of 31.0082102588036% for the Past 3 years.
  • The company has an efficient Cash Conversion Cycle of 80.46752486812 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.00665547974546.

 Limitations

  • The company has shown a poor profit growth of 4.78779285541899% for the Past 3 years.
  • The company is trading at a high PE of 52.7.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021
Net Sales 33.6 45.57 41.12 45.25 54.76
Total Expenditure 30.2 42.51 39.56 43.66 50.68
Operating Profit 3.4 3.06 1.56 1.59 4.08
Other Income 0 0 1.26 0 0
Interest 0.92 1.19 1.29 0.64 1.05
Depreciation 0.49 0.53 0.52 0.51 0.52
Exceptional Items -1.16 0 0 0 0
Profit Before Tax 0.83 1.34 1.01 0.44 2.51
Tax 0 0 0.28 0.12 0.67
Profit After Tax 0.83 1.34 0.73 0.33 1.84
Adjusted EPS (Rs) 2.07 3.35 1.82 0.82 4.61

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Net Sales 56.7 59.55 97.02 112.77 133.89
Total Expenditure 53.37 53.84 86.99 104.44 124.55
Operating Profit 3.32 5.71 10.03 8.33 9.35
Other Income 1.91 0.16 0.58 0.52 1.4
Interest 1.87 1.95 3.12 4.47 4.37
Depreciation 1.14 1.29 1.33 1.88 2
Exceptional Items 0 0 0 0 -1.16
Profit Before Tax 2.23 2.64 6.16 2.49 3.21
Tax 0.8 0.89 1.7 0.59 1.19
Net Profit 1.43 1.75 4.46 1.9 2.01
Adjusted EPS (Rs.) 5.36 4.16 11.18 4.77 5.05

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Equity and Liabilities
Share Capital 4.87 3.43 3.99 3.99 3.99
Total Reserves 2.39 18.74 35 37.33 39.08
Borrowings 7.24 0 10.64 11.5 29.11
Other N/C liabilities 1.13 4.06 1.88 2.57 2.98
Current liabilities 40.47 53.04 53.41 85.99 86.46
Total Liabilities 56.1 79.26 104.91 141.38 161.62
Assets
Net Block 20.5 16.28 31.35 30.97 30.35
Capital WIP 0 11.15 0 0 0
Intangible WIP 0 0 0 0 0
Investments 0 0 0 0 0
Loans & Advances 0.35 0.35 1.03 1.08 1.18
Other N/C Assets 0 0 0 0 0
Current Assets 35.24 51.48 72.52 109.32 130.08
Total Assets 56.1 79.26 104.91 141.38 161.62
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Profit from operations 2.23 1.75 6.18 2.35 2.01
Adjustment 2 2.67 2.08 6.03 8.63
Changes in Assets & Liabilities -0.25 12.88 -7.43 -19.02 -10.48
Tax Paid 0 0 0 0 0
Operating Cash Flow 3.97 17.3 0.84 -10.64 0.17
Investing Cash Flow -7.13 -8.21 -5.25 -1.49 -1.39
Financing Cash Flow 2.52 -8.38 4.43 13.73 -0.71
Net Cash Flow -0.64 0.7 0.01 1.59 -1.93

Corporate Actions

Investors Details

PARTICULARS Sep 2020% Dec 2020% Mar 2021% Jun 2021% Sep 2021%
Promoters 52.04 52.04 52.04 52.04 52.04
daulat nariman med... 33.60 33.60 - 33.60 31.60
daulat nariman med... - - 33.60 - -
nariman medhora 14.42 14.42 - 14.42 14.42
nariman medhora - - 14.42 - -
fredun nariman med... 4.01 4.01 - 4.01 4.01
fredun nariman med... - - 4.01 - -
nirmala chopra . - - - - 2.01
PARTICULARS Sep 2020% Dec 2020% Mar 2021% Jun 2021% Sep 2021%
Investors 47.96 47.96 47.96 47.96 47.96
nikhil vora 5.85 - - 5.85 5.85
nikhil vora - - 5.85 - -
bank of india 3.76 1.88 - 1.88 3.76
india max investme... - - - - 1.68
bank of india - - 1.88 - -
s s seema 1.51 - - - 1.50
gothamchand a - - - - 1.00
k r karthikeyan - - - - 1.00
s s seema - - 1.05 - -
rudra murthy b v . 1.04 - - 1.04 1.04
rudra murthy b v . - - 1.04 - -
vachana investment... - - - - -
urmiladevi taparia - - - - 1.00
llp - - 0.02 - 0.01
venture capital fu... - - - 0.02 -

Annual Reports

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Fredun Pharma Stock Price Analysis and Quick Research Report. Is Fredun Pharma an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Fredun Pharma and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 0.169934734 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Fredun Pharma has a Debt to Equity ratio of 0.9204 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Fredun Pharma , the EPS growth was 5.92591038764893 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Fredun Pharma has OPM of 6.98075154662785 % which is a bad sign for profitability.
     
  • ROE: Fredun Pharma have a poor ROE of 4.77456622831975 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Fredun Pharma

X